Results 81 to 90 of about 33,530 (249)

Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Methodist DeBakey Cardiovascular Journal
Chronic thromboembolic pulmonary hypertension is a rare form of pulmonary hypertension in patients who have evidence of chronic thromboembolic occlusion of the pulmonary vasculature.
Lauren N. Carlozzi, C. Huie Lin, Zachary L. Steinberg   +2 more
doaj   +1 more source

Update on Chronic Thromboembolic Pulmonary Hypertension [PDF]

Circulation, 2014
Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct pulmonary vascular disease caused by chronic obstruction of major pulmonary arteries that is amenable to cure by pulmonary endarterectomy (PEA). Main features of CTEPH as opposed to pulmonary arterial hypertension (PAH) are a nonhomogeneous distribution of disease in segments of the ...
Irene Marthe, Lang, Michael, Madani
openaire   +2 more sources

Healthcare utilization in chronic thromboembolic pulmonary hypertension after acute pulmonary embolism

, 2018
Essentials Diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH) is long. We explored healthcare utilisation of patients diagnosed with CTEPH after pulmonary embolism.
Symersky, P., Huisman, M.V., Meijboom, L J, Klok, F A, Bogaard, H.J., Huisman, M V, Hout, W.B. van den, Vonk-Noordegraaf, A, Ende-Verhaar, Y.M., Vonk-Noordegraaf, A., Ende-Verhaar, Y M, Symersky, P, Meijboom, L.J., Bogaard, H J, van den Hout, W B, Klok, F.A.   +15 more
core   +1 more source

Familial Chronic Thromboembolic Pulmonary Hypertension [PDF]

Chest, 2016
Chronic thromboembolic pulmonary hypertension (CTEPH) is an uncommon disease that is the most serious complication associated with unresolved pulmonary embolism. This disease has several risk factors, but no familial pattern has been described. Few thrombophilic conditions have been reported to increase risk of CTEPH, and none of the hereditary ...
Julianna, Desmarais, C Gregory, Elliott
openaire   +2 more sources

Safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension in the Netherlands

, 2020
Background: Balloon pulmonary angioplasty (BPA) is an emerging treatment in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic disease (CTED).
Rensing, B. J. W. M., Symersky, P., Post, M. C., Rensing, B. J.W.M., Meijboom, L. J., van Thor, M. C.J., Bogaard, H. J., Vonk Noordegraaf, A., Braams, N. J., Beijk, M. A. M., van den Heuvel, D. A. F., van den Heuvel, D. A.F., Mager, J. J., Heijmen, R. H., ten Klooster, L., Nossent, E. J., Beijk, M. A.M., van Thor, M. C. J., Lely, R. J., Snijder, R. J.   +19 more
core   +1 more source

Impact of Gentamicin‐Impregnated Collagen Sponge on the Incidence of Access Related Infections After Full‐Support Microaxial Flow Pump Therapy

Artificial Organs, EarlyView.
Local application of gentamicin for wound closure after full‐support microaxial flow pump therapy. ABSTRACT Background Surgically implanted microaxial flow pumps (mAFP) are increasingly used for cardiogenic shock treatment. Standard mAFP explantation is performed bedside with a shortening of the vascular prosthesis, which may represent a potential ...
Gaik Nersesian, Maximilian Rauch, Daniel Lewin, Leonard Pitts, Julius Kaemmel, Anna Stegmann, Julia Stein, Yuriy Hrytsyna, Felix Schoenrath, Volkmar Falk, Evgenij Potapov, Pia Lanmueller   +11 more
wiley   +1 more source

Neutrophil extracellular traps induced by activated platelets as a cause of neutrophil–platelet aggregation in β‐thalassaemia/haemoglobin E patients

British Journal of Haematology, EarlyView.
Abnormal neutrophils and platelets in splenectomised β‐thalassaemia/haemoglobin E (HbE) disease contribute to neutrophil–platelet aggregation, leading to a high risk of thrombus formation. Activated platelets induce neutrophils to generate neutrophil extracellular trap (NETs) via the P‐selectin–P‐selectin glycoprotein ligand‐1 (PSGL1) pathway, which ...
Rattanawan Thubthed, Rattanaporn Praneetponkang, Potchaman Sittipaisankul, Chayada Thiengtavor, Suwathida Chumpuchanaphai, Kittiphong Paiboonsukwong, Suthat Fucharoen, Kovit Pattanapanyasat, Jim Vadolas, Duncan R. Smith, Saovaros Svasti, Pornthip Chaichompoo   +11 more
wiley   +1 more source

Pulmonary hypertension in patients with chronic myeloproliferative disorders

European Respiratory Review, 2015
Pulmonary hypertension (PH) is a major complication of several haematological disorders. Chronic myeloproliferative diseases (CMPDs) associated with pulmonary hypertension have been included in group five of the clinical classification for pulmonary ...
Yochai Adir, Davide Elia, Sergio Harari
doaj   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

British Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas   +5 more
wiley   +1 more source

Chronic thromboembolic pulmonary hypertension: approaches to diagnosis and treatment

Медицинский совет, 2013
The article tells about incidence of pulmonary hypertension after pulmonary artery thromboembolia; congenital and acquired coagulation abnormalities in patients with venous thromboembolism; potential factors of chronic thromboembolic pulmonary ...
N. A. Shostak, A. A. Klimenko, N. A. Demidova, S. M. Sorokoletov, K. V. Razumov, N. M. Babadaeva   +5 more
doaj   +1 more source